| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40765ca9a78b54a8a76f781d159ad145 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 |
| filingDate |
2020-01-13^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fc4f58470ab46247b6c9127bf1e7910
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07b62ffe3665420bb477c49b987c8fed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67459232b755b3a4217b30090070a03b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a89fd39bd335fd2108a6aa8a154b2ab0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41ce955490e685b6c5d8c7e4a7fe8ed4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27a6bf1c41c77da28f610d5049b39357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae55ccb4041a1c90d81d0b4bd12fb397 |
| publicationDate |
2021-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3911647-A1 |
| titleOfInvention |
Fxr (nr1h4) modulating compounds |
| abstract |
The present disclosure relates generally to a compound of formula (I) that binds to FXR and acts as agonists of FXR. The disclosure further relates to the use of the compound for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compound. |
| priorityDate |
2019-01-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |